


Reframing Outcomes: Number Needed to Treat (NNT) vs Number Needed to Harm (NNH)

Jeannie Chan, PharmD, MPH




We need to talk about MATH!



- Statistics is the math we use to demonstrate relationships or establish the *lack of* relationships.
- Statistics is "sophisticated math" that requires interpretation



Observation alone can lead us astray.....




Though each was partly in the right, all were in the wrong.

https://www.sloww.co/blind-men-elephant/

Slide Courtesy of Zahra K. Escobar PharmD




Quality of Evidence





Strength of Recommendation







Number Need to Treat (NNT)

Intervention Group: 90% efficacy

Control Group: 80% efficacy



shutterstock.com · 1415575436



shutterstock.com · 1415575439







- Absolute Risk Reduction (ARR)
 - Difference between the event rate in control group and intervention group
 - 90% 80% = 10% = 0.1


- Number Needed to Treat (NNT)
 - Inverse of the absolute risk reduction (ARR) expressed as a decimal.
 - NNT = 1/ARR
 - NNT = 1/0.1 = 10




Number Need to Harm (NNH)

Control Group: 11% ADR

Intervention Group: 12% ADR





shutterstock.com · 2043162245









- Absolute Risk Increase (ARI)
 - Difference between the event rate in control group and intervention group
 - 12% 11% = 1% = 0.01

- Number Needed to Harm (NNH)
 - Inverse of the absolute risk increase (ARI) expressed as a decimal.
 - NNH = 1/ARI
 - NNH = 1/0.01 = 100



Balancing Efficacy and Toxicity

Efficacy

Number needed to Treat (NNT)

Toxicity

Number needed to Harm (NNH)




CAMERA-2 Trial

JN **JAMA** Network[®]

QUESTION In adults with methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia, does the addition of 7 days of an antistaphylococcal β-lactam to standard antibiotic therapy (vancomycin or daptomycin) lead to improved clinical outcomes at 90 days?

CONCLUSION This randomized trial found that the addition of an antistaphylococcal β -lactam to standard antibiotic therapy did not significantly reduce the primary composite end point in patients with MRSA bacteremia.



Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal ß-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial [published February 11, 2020]. JAMA. doi:10.1001/jama.2020.0103

Let's look at AKI

Secondary Outcomes ^c				
All-cause mortality ^d				
Day 14	13/170 (8)	13/174 (7)	0.2 (-5.4 to 5.8)	.95
Day 42	25/170 (15)	19/174 (11)	3.8 (-3.3 to 10.8)	.29
Day 90	35/170 (21)	28/174 (16)	4.5 (-3.7 to 12.7)	.28
Persistent bacteremia ^e				
Day 2	50/167 (30)	61/173 (35)	-5.3 (-15.3 to 4.6)	.29
Day 5	19/166 (11)	35/172 (20)	-8.9 (-16.6 to -1.2)	.02
Microbiological relapse ^a	14/169 (8)	18/175 (10)	-2.0 (-8.1 to 4.1)	.52
Microbiological treatment failure ^a	16/170 (9)	17/175 (10)	-0.3 (-6.5 to 5.9)	.92
Acute kidney injury ^f	34/145 (23)	9/145 (6)	17.2 (9.3 to 25.2)	<.001
Duration of intravenous antibiotics, mean (SD), d	29.3 (19.5)	28.1 (17.4)		.72


Absolute Risk Increase (ARI) = 23% - 6% = 17% = 0.17

Number Needed to Harm (NNH) = 1/0.17 = 6

If we give combination therapy to all patients with MRSA bacteremia, 1 out of 6 patients may develop harm (AKI)



DOOR Analysis – Desirability of Outcome Ranking



Evans S, et al. Clinical Infectious Diseases. 2015; 61(5):800-806. Slide Courtesy of Joanne Huang PharmD



CAMERA-2 and DOOR analysis

A post hoc analysis of the CAMERA2 trial using a desirability of outcome ranking (DOOR) approach

Petersiel et al. 2024 | Open Forum Infectious Diseases

STUDY POPULATION



342 participants from the CAMERA2 trial analyzed





173 allocated to standard therapy with vancomycin (or daptomycin) 169 allocated to combination of standard therapy with a β-lactam

METHODS

Each participant was assigned a DOOR category: 1- alive and none of: bacteremia persistence OR infection relapse OR adverse events 2- alive with 1 of the above 3- alive with 2 of the above 4 -alive with all 3 of the above 5- dead

Within each DOOR category further ranking was done according to hospital length of stay (LOS) and duration of intravenous antibiotic treatment (RADAR)



When considering both efficacy and safety, treatment of MRSA bacteremia with a combination of standard therapy and a β-lactam likely results in a worse clinical outcome than standard therapy

Open Forum Infectious Diseases

https://doi.org/10.1093/ofid/ofae181

0008

Table 2. Distribution of Participants Within Desirability of Outcome Ranking Categories for the CAMERA2 Trial by Treatment Group^a

DOOR Category	Standard Therapy, No. (%) (n = 173)	Combination Therapy, No. (%) (n = 169)
1	99 (57.2)	82 (48.5)
2	35 (20.2)	42 (24.9)
3	11 (6.4)	8 (4.7)
4	0	2 (1.2)
5	28 (16.2)	35 (20.7)

Abbreviations: CAMERA2, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus; DOOR, desirability of outcome ranking.

^aData on 2 of the DOOR components were missing for 10 participants, who were excluded from the primary analysis: Data on 90-day mortality were missing for 6 participants (1.7%, 3 from each arm), and data on persistent bacteremia were missing for 4 participants (1.1%, 2 from each arm).




Figure 1. Desirability of outcome ranking (DOOR) distribution according to treatment groups: primary analysis. The DOOR is ranked from 1 (best) to 5 (worst). Percentages for each category are indicated within the bars.



Reframing Conclusions

• JAMA (Original analysis):

 This randomized trial found that the addition of an antistaphylococcal β-lactam to standard antibiotic therapy <u>did</u> <u>not significantly reduce the primary composite endpoint</u> (90-day mortality, persistent bacteremia at day 5, or microbiological relapse/failure) in patients with MRSA bacteremia

• OFID (DOOR analysis):

• When <u>considering both efficacy and safety</u>, treatment of MRSA bacteremia with a combination of standard therapy and a β -lactam <u>likely results in a worse clinical outcome</u> than standard therapy



Summary

 NNT – relative benefits of a given intervention. The lower the number, the more effective the treatment.

 NNH – relative harms of a given intervention. The higher the number, the safer the intervention.

 Desirability of outcome ranking – more pragmatic approach (balancing efficacy/toxicity)